AKBA vs FRT · rev $102.7M vs rev $1.28B
Akebia Ther (AKBA) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
FRT (FRT) common stock.
Latest reported AKBA revenue for 2026-06-30 was $102.7M. Net income was -$18.0M. Revenue was up 91.8% from 2026-03-31 to 2026-06-30. AKBA currently screens at market cap $260.1M.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
AKBA currently screens at market cap $260.1M. FRT currently screens at market cap $0.
Not investment advice. Open the AKBA and FRT stock pages for the full models.
Not investment advice.